O. Lipatov

发表

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

R. Motzer, C. Sternberg, P. Tomczak, 2018, European journal of cancer.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

R. Greil, F. André, V. Semiglazov, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

M. Parmar, J. Mackey, D. Cameron, 2013, The Lancet. Oncology.

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Ahn， Jin Hee, S. Loi, D. Cescon, 2020, The Lancet.

A phase II study of picoplatin (pico) as second-line therapy for patients (pts) with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum (plat)-containing chemotherapy

O. Lipatov, J. Eckardt, H. Breitz, 2007 .

M. Candelaria, O. Lipatov, S. Beniwal, 2019, Leukemia & lymphoma.

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

E. Tokunaga, I. Bondarenko, O. Lipatov, 2022, BioDrugs.

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)

O. Lipatov, D. Sakaeva, A. Pushkarev, 2021 .

2509 Overall survival analysis from a randomised phase III trial of axitini vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma

N. Vogelzang, Thomas E. Hutson, O. Lipatov, 2015 .

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

K. Gelmon, H. Rugo, N. Harbeck, 2019, Breast Cancer Research and Treatment.

Axitinib Versus Sorafenib in First‐Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

N. Vogelzang, Thomas E. Hutson, O. Lipatov, 2017, Clinical genitourinary cancer.

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

S. Loi, D. Cescon, V. Karantza, 2022, The New England journal of medicine.

Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer

K. Blackwell, N. Harbeck, O. Lipatov, 2016, Future oncology.

Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.

E. Van Cutsem, F. Lordick, A. Sawaki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Naotoshi Sugimoto, Yasuhiro Shimada, David Ferry, 2014, The Lancet. Oncology.

Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

E. Perez, N. Robert, J. O’Shaughnessy, 2009 .

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

E. Perez, N. Robert, V. Diéras, 2009 .

Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study

O. Lipatov, N. Sultanbaeva, A. Nasretdinov, 2022, Journal of Modern Oncology.

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

R. Motzer, A. Berkenblit, C. Sternberg, 2012 .

HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial

A. Sawaki, H. Chung, L. Shen, 2008 .

Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

D. Doval, W. Slichenmyer, R. Chacko, 2010 .

Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).

R. Chacko, P. Bhargava, O. Lipatov, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC).

D. Doval, A. Strahs, W. Slichenmyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)

E. Popova, O. Lipatov, N. Sultanbaeva, 2022, Creative surgery and oncology.

PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).

K. Gelmon, H. Rugo, N. Harbeck, 2016 .

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, F. André, V. Semiglazov, 2011 .

Palbociclib and Letrozole in Advanced Breast Cancer.

K. Gelmon, H. Rugo, N. Harbeck, 2016, The New England journal of medicine.

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†

Y. Shimada, E. Van Cutsem, N. Sugimoto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.

E. Winer, J. Mejia, V. Karantza, 2021, The Lancet. Oncology.

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

R. Motzer, D. Cella, A. Berkenblit, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.

D. Doval, A. Strahs, W. Slichenmyer, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

S. Loi, D. Cescon, V. Karantza, 2020 .

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

Xian Zhou, Edith A Perez, E. Perez, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC).

E. Perez, N. Robert, V. Diéras, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Off-Label Drug Use in Oncology

O. Lipatov, D. Sakaeva, E. Karabina, 2022, Creative surgery and oncology.

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.

O. Lipatov, J. Eckardt, H. Breitz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

N. Vogelzang, V. Lesovoy, Thomas E. Hutson, 2013, The Lancet. Oncology.

a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

M. Buyse, K. Gelmon, J. Mackey, 2014 .

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

K. Gelmon, R. Finn, S. Im, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

E. Tokunaga, I. Bondarenko, O. Lipatov, 2022, BioDrugs.

Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene

O. Lipatov, A. Pushkarev, N. Sultanbaeva, 2020, Meditsinskiy sovet = Medical Council.

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

E. Winer, S. Loi, J. Mejia, 2020 .

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

S. Loi, D. Cescon, V. Karantza, 2021, Annals of Oncology.

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

S. Loi, D. Cescon, V. Karantza, 2021 .

KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)

J. Mejia, V. Karantza, F. André, 2019, Annals of Oncology.

Supportive care against correcting protein-energy malnutrition in patients with generalized gastrointestinal cancer

O. Lipatov, O. M. Petrova, L. N. Kudryashova, 2023, Creative surgery and oncology.

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

R. Motzer, A. Berkenblit, C. Sternberg, 2012 .

Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.

J. Lunceford, E. Winer, J. Mejia, 2020 .

476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1

E. Perez, N. Robert, V. Diéras, 2010 .

Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).

C. Sternberg, P. Tomczak, Thomas E. Hutson, 2015 .

Activity of tivozanib (AV-951) in patients (Pts) with different histologic subtypes of renal cell carcinoma (RCC).

D. Doval, W. Slichenmyer, R. Chacko, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.

Tae-You Kim, N. Sugimoto, G. Bodoky, 2014 .

Efficacy of Off-Label Use of Anticancer Drugs in Oncology

O. Lipatov, D. Sakaeva, E. Karabina, 2023, Creative surgery and oncology.

Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups

K. Gelmon, N. Harbeck, R. Finn, 2018 .

Breast cancer screening in germline mutation carriers. A literature review

O. Lipatov, N. Sultanbaeva, A. Nasretdinov, 2023, Tumors of female reproductive system.

Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer

K. Blackwell, N. Harbeck, O. Lipatov, 2016 .

Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan

S. Gantsev, O. Lipatov, K. Menshikov, 2020, Creative surgery and oncology.

Sunitinib in the treatment of advanced renal cell carcinoma

O. Lipatov, N. Sultanbaeva, A. Nasretdinov, 2023, Meditsinskiy sovet = Medical Council.

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

R. Motzer, A. Berkenblit, C. Sternberg, 2012 .

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

M. Parmar, J. Mackey, D. Cameron, 2013, The Lancet. Oncology.